According to the Changchun Hi-Tech announcement, the subsidiary Jinsai Pharmaceutical has received the “Notice of Acceptance” approved and issued by the State Drug Administration, and its application for clinical trial registration of GenSci 141 Ointment has been accepted. This drug is dihydrotestosterone ointment, which belongs to the chemical class 2.2 and 2.4, and is used to improve small penises in children. If clinical trials progress smoothly, it will help the company expand its business and optimize its product structure. However, pharmaceutical product development cycles are long and there are many steps, and there is uncertainty about the clinical trial process.

According to the Changchun Hi-Tech announcement, the subsidiary Jinsai Pharmaceutical has received the “Notice of Acceptance” approved and issued by the State Drug Administration, and its application for clinical trial registration of GenSci 141 Ointment has been accepted. This drug is dihydrotestosterone ointment, which belongs to the chemical class 2.2 and 2.4, and is used to improve small penises in children. If clinical trials progress smoothly, it will help the company expand its business and optimize its product structure. However, pharmaceutical product development cycles are long and there are many steps, and there is uncertainty about the clinical trial process.